Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12104/43551
Title: Pharmacogenetics and antiepileptic drug metabolism: Implication of genetic variants in cytochromes P450 [Farmacogenética y metabolismo de formacos antiepilépticos: Implicación de variantes genéticas en citocromos P1450]
Author: Rincon-Sanchez, A.R.
Covarrubias, A.
Rivas-Estilla, A.M.
Pedraza-Chaverri, J.
Cruz, C.
Islas-Carbajal, M.C.
Panduro-Cerda, Arturo
Estanes, A.
Armendariz-Borunda, J.
Issue Date: 2005
Abstract: In this study, we evaluated the effect of prostaglandin E2 (PGE2) on renal and hepatic function using an experimental cirrhosis model plus acute liver damage (ALD). Male Wistar rats treated with carbon tetrachloride (CCl4) for 8 weeks were used for the cirrhosis model. Cirrhotic rats were further exposed to an additional acute dose of CCl 4 to induce ALD and then treated with PGE2 intramuscularly twice a day for 7 days (200 ?g/Kg/day). PGE2 administration started 3 h after the additional dosing of CCl4 and PGE2 effect on hepatorenal function was examined on days 1, 2, 3, and 7. PGE 2-treatment ameliorated the decrease in urinary sodium excretion, and normalized serum activities of aspartate aminotransferase (AST), alanine aminotransferase (ALT) and plasma renin observed in cirrhotic rats with ALD. In addition, PGE2-treatment decreased mean arterial pressure, glomerular hypercellularity and thickening of the kidney capillary wall, and liver steatosis and cellular necrosis. Also, PGE2 increased the number of regenerative nodules. Finally, PGE2-treatment inhibited the increase in Alpha 1-acid glycoprotein (pAGP), fibrinogen, and Apo A-1 mRNA expression by 83%, 59%, and 77%, respectively. These results suggest that PGE2 administration may decrease the expression of acute phase proteins. In conclusion, PGE2-treatment improved hepatic and renal function and may be useful to down-regulate the acute phase response in cirrhotic rats presenting ALD induced by CCl4. " 2004 Elsevier GmbH. All rights reserved.",,,,,,"10.1016/j.etp.2004.10.003",,,"http://hdl.handle.net/20.500.12104/43551","http://www.scopus.com/inward/record.url?eid=2-s2.0-14644424576&partnerID=40&md5=e679c9ae8f77189edf81017e6c45f90a",,,,,,"04-may",,"Experimental and Toxicologic Pathology",,"291
303",,"56",,"Scopus
WOS",,,,,,"Acute liver damage; Decompensated cirrhosis; Experimental cirrhosis; Prostaglandin E2",,,,,,"PGE2 alleviates kidney and liver damage, decreases plasma renin activity and acute phase response in cirrhotic rats with acute liver damage",,"Article" "45331","123456789/35008",,"Escutia Gutiérrez, R., Jalisco Pain Relief and Palliative Care Institute, Mexico, Department of Health, Jalisco, Mexico; Cortéz Álvarez, C.R., Faculty of Exact Sciences and Engineering, University of Guadalajara, Guadalajara, Mexico; Álvarez Álvarez, R.M., Jalisco Pain Relief and Palliative Care Institute, Mexico, Department of Health, Jalisco, Mexico; Flores Hernández, J.L.V., Physiology Institute, Autonomous University of Puebla, Puebla, Mexico; Gutiérrez Godínez, J., Pharmaceutical Services Office, Autonomous University of Puebla, Puebla, Mexico; López y López, J.G., Pharmaceutical Services Office, Autonomous University of Puebla, Puebla, Mexico",,"Escutia Gutierrez, R.
Cortez Alvarez, C.R.
Alvarez Alvarez, R.M.
Flores Hernandez, J.L.V.
Gutierrez Godinez, J.
Lopez y Lopez, J.G.",,"2007",,"Neither the purchase nor the distribution of pharmaceuticals in hospitals and community pharmacies in Mexico is under the care of pharmacists. Some are under control of physicians. This report presents the results of the implementation of somef pharmaceutical services for the Jalisco Pain Relief, and Palliative Care Institute (Palia Institute), under the direction of the Secretary of Health, Government of Jalisco. The services implemented were drug distribution system, Drug Information Service, Pharmacovigilance Program, and home pharmacotherapy follow-up pilot program for patients with advanced illness, with the ultimate using the appropriate medication. The drug distribution system included dispensing of opioid pain medications, antidepressants, anticonvulsants, NSAIDs, anxiolytic drugs, steroid drugs, laxatives, and anti-emetics. The frequently used drugs were morphine sulfate (62%), amitriptyline (6.4%), and dextropropoxyphene (5.8%). The Drug Information Service answered 114 consultations, mainly asked by a physician (71%) concerned with adverse drug reactions and contraindications (21%). The pharmacovigilance program identified 146 suspected adverse drug reactions and classified them reasonably as possible (27%), probable (69%), and certain (4%). These were attributed mainly to pregabalin and tramadol. The home pharmacotherapy follow-up pilot program cared patients with different cancer diagnoses and drug-related problems (DRP), which were identified and classified (according to second Granada Consensus) for pharmaceutical intervention as DRP 1 (5%), DRP 2 (10%), DRP 3 (14%), DRP 4 (19%), DRP 5 (24%), or DRP 6 (28%). This report provides information concerning the accurate use of medication and, above all, an opportunity for Mexican pharmacists to become an part of health teams seeking to resolve drug-related problems.",,,,,,,,,"http://hdl.handle.net/20.500.12104/43552","http://www.scopus.com/inward/record.url?eid=2-s2.0-37349024314&partnerID=40&md5=afcb181515769892e89b64375693d02b
http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=prem&AN=25170355",,,,,,"4",,"Pharmacy Practice",,"174
178",,"5",,"Scopus
MEDLINE",,,,,,"Adverse Drug reaction reporting systems; Drug toxicity; Mexico",,,,,,"Pharmaceutical services in a Mexican pain relief and palliative care institute",,"Article" "45332","123456789/35008",,"Saldaña-Cruz, A.M., División de Medicina Molecular; Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico; Sánchez-Corona, J., División de Medicina Molecular; Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico; Márquez de Santiago, D.A., División de Medicina Molecular; Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico; García-Zapién, A.G., División de Medicina Molecular; Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico; Flores-Martínez, S.E., División de Medicina Molecular; Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico",,"Saldana-Cruz, A.M.
Sanchez-Corona, J.
Marquez de Santiago, D.A.
García-Zapien, A.G.
Flores-Martinez, S.E.",,"2013",,"Introduction. Antiepileptic drugs (AEDs) are used for the seizures control in patients with epilepsy, however 20-30% of epileptic patients are drug resistant. Several factors contributing to the variability of the AEDs response, and this variability can be partially attributed to the presence of sequence variations (polymorphisms) in genes encoding enzymes involved in the AEDs metabolism. Aim. To describe the polymorphisms in genes that encoding for proteins involved in the metabolism of some of the major AEDs, focusing on enzymes cytochrome P450 (CYP450). Development. There are some polymorphisms in genes encoding proteins involved in drug metabolism, particularly enzymes of superfamily CYP450, that are already considered of clinical utility in the therapeutic management. These genetic variants contribute to the variability of the activity of metabolizing enzymes, which in turn influencing the poor or inadequate therapeutic response, as well as in the occurrence of adverse effects. Conclusions. The identification of interindividual variability in the response to AEDs may allow the personalized treatment with the aim of maximize the efficiency and minimize risk, regardless of the clinical variability and adverse effects could be manifest in a minority of the patients. " 2013 Revista de Neurología.
URI: http://hdl.handle.net/20.500.12104/43553
http://www.scopus.com/inward/record.url?eid=2-s2.0-84877687819&partnerID=40&md5=0e303f70298789ea108746985d431601
Appears in Collections:Producción científica UdeG

Files in This Item:
There are no files associated with this item.


Items in RIUdeG are protected by copyright, with all rights reserved, unless otherwise indicated.